VCYT - Veracyte, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$45.25
DETAILS
HIGH:
$52.00
LOW:
$37.00
MEDIAN:
$46.00
CONSENSUS:
$45.25
UPSIDE:
0.49%
Institutional Holders (13F)
| GURU | SHARES | VALUE | WEIGHT % | SHARES CHG | ACTION |
|---|---|---|---|---|---|
| Wood | 483,904 | $15.6M | 0.0% | +57,675 | INCREASED |
| Dalio | 91,590 | $3.0M | 0.0% | +63,196 | INCREASED |
| Greenblatt | 72,475 | $2.3M | 0.0% | +2,903 | INCREASED |
| Cooperman | 42,135 | $1.4M | 0.0% | +42,135 | INCREASED |
Insider Trading
| DATE | INSIDER | TITLE | TYPE | SHARES | PRICE | VALUE |
|---|---|---|---|---|---|---|
| 2026-05-20 | EPSTEIN ROBERT S | director | SELL | 10,000 | $44.01 | $440K |
| 2026-05-06 | McGuire Annie | officer: SVP, General Counsel | SELL | 5,102 | $40.00 | $204K |
| 2026-04-10 | Haas Kevin Richard | officer: Chief Dev and Tech Officer | A-Award | 44,221 | -- | -- |
| 2026-03-24 | Haas Kevin Richard | officer | ? | -- | -- | -- |
| 2026-03-06 | Wygant Jonathan | officer: VP, Chief Accounting Officer | A-Award | 10,525 | -- | -- |
| 2026-03-06 | McGuire Annie | officer: SVP, General Counsel | A-Award | 26,314 | -- | -- |
| 2026-03-06 | Stapley Marc | director, officer: Chief Executive Officer | A-Award | 92,099 | -- | -- |
| 2026-03-06 | Chambers Rebecca | officer: Chief Financial Officer | A-Award | 13,157 | -- | -- |
| 2026-03-06 | Chambers Rebecca | officer: Chief Financial Officer | A-Award | 36,181 | -- | -- |
| 2026-03-06 | Leite John | officer: Chief Commercial Officer-CLIA | A-Award | 36,181 | -- | -- |
| 2026-03-06 | McGuire Annie | officer: SVP, General Counsel | A-Award | 32,892 | -- | -- |
| 2026-03-06 | Febbo Phillip G. | officer: Chief Scientific & Med Officer | A-Award | 6,578 | -- | -- |
| 2026-03-06 | Febbo Phillip G. | officer: Chief Scientific & Med Officer | A-Award | 29,603 | -- | -- |
| 2026-03-06 | Leite John | officer: Chief Commercial Officer-CLIA | A-Award | 6,578 | -- | -- |
| 2026-03-04 | Chambers Rebecca | officer: Chief Financial Officer | SELL | 4,400 | $35.55 | $156K |
| 2026-03-04 | Chambers Rebecca | officer: Chief Financial Officer | SELL | 13,941 | $36.33 | $506K |
| 2026-03-04 | McGuire Annie | officer: SVP, General Counsel | SELL | 1,664 | $36.34 | $60K |
| 2026-03-04 | Stapley Marc | director, officer: Chief Executive Officer | SELL | 19,244 | $35.56 | $684K |
| 2026-03-04 | Stapley Marc | director, officer: Chief Executive Officer | SELL | 26,279 | $36.28 | $953K |
| 2026-03-04 | Leite John | officer: Chief Commercial Officer-CLIA | SELL | 5,260 | $35.19 | $185K |
| 2026-03-04 | McGuire Annie | officer: SVP, General Counsel | SELL | 4,994 | $35.29 | $176K |
| 2026-03-02 | Wygant Jonathan | officer: VP, Chief Accounting Officer | F-InKind | 3,006 | $36.01 | $108K |
| 2026-03-02 | Chambers Rebecca | officer: Chief Financial Officer | F-InKind | 7,234 | $36.01 | $260K |
| 2026-03-02 | Febbo Phillip G. | officer: Chief Scientific & Med Officer | F-InKind | 6,035 | $36.01 | $217K |
| 2026-03-02 | Leite John | officer: Chief Commercial Officer-CLIA | F-InKind | 7,517 | $36.01 | $271K |